Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o1/07/96 \ \ Origin: Appendix 5 \ \ Amended o1/07/98, o1/09/99, o1/07/00, 30/09/01, 11/03/02, o1/01/03, 24/10/05, o1/08/12, o4/03/13$ 

Name of entity

#### **BANNERMAN RESOURCES LIMITED**

ABN

34 113 017 128

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- <sup>+</sup>Class of <sup>+</sup>securities issued or to be issued
- 1. Performance Rights (Unlisted)
- 2. Non-Executive Director Share Rights (Unlisted)
- 3. Non-Executive Director Options (Unlisted)
- 4. Share Rights (Unlisted)
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- 1. 26,416,100 Performance Rights (Unlisted)
- 862,100 Non-Executive Director Share Rights (Unlisted)
- 3. 7,846,000 Non-Executive Director Options (Unlisted)
- 4. 473,200 Share Rights (Unlisted)

<sup>+</sup> See chapter 19 for defined terms.

Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

#### 1. Performance Rights (Unlisted)

Performance Rights will be granted on the following key terms in accordance with the Employee Incentive Plan as approved by shareholders on 22 November 2013:

- (i) 13,208,050 Performance Rights subject to the Company's relative share price performance versus a comparator group of uranium development companies, split as follows:
  - a. 10,741,150 Performance Rights assessed for vesting after three
     (3) years on 15 November 2018; and
  - b. 2,466,900 Performance Rights assessed for vesting after two (2) years on 15 November 2017.
- (ii) 13,208,050 Performance Rights subject to attainment of defined individual and group performance criteria, assessed by the Board in line with the Company's operating plans, split as follows:
  - a. 10,741,150 Performance Rights assessed for vesting after three
     (3) years on 15 November 2018; and
  - b. 2,466,900 Performance Rights assessed for vesting after two (2) years on 15 November 2017.

To the extent that the performance criteria for any of the Performance Rights are not satisfied, the Performance Rights will lapse and be cancelled.

Each holder of Performance Rights is entitled to one ordinary fully paid share for each Performance Right that vests.

There is no consideration payable upon the grant or vesting of Performance Rights.

In case of a change of control, Performance Rights that remain subject to a vesting condition immediately vest.

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## 2. Non-Executive Director Share Rights (Unlisted)

862,100 Non-Executive Director Share Rights will be granted in accordance with the terms of the Non-Executive Director Share Incentive Plan (**NEDSIP**) as approved by shareholders on 11 November 2015.

Non-Executive Director Share Rights will vest on 15 November 2016, subject to the Director continuing to provide services as a Director of the Company or as otherwise in accordance with the NEDSIP.

Each holder of a Non-Executive Director Share Right is entitled to one ordinary fully paid share for each Share Right that vests and there is no consideration payable upon the grant or vesting of a Share Right.

In case of a change of control, Share Rights that remain subject to a vesting condition immediately vest.

## 3. Non-Executive Director Options (Unlisted)

7,846,000 Non-Executive Director Options will be granted in accordance with the terms of the NEDSIP approved by shareholders on 11 November 2015.

Non-Executive Director Options will have an exercise price of A\$0.044 per share (being a 50% premium to the 20 Business Day VWAP of A\$0.029 per Bannerman share at the close of trade on 24 December 2015) and expire on 15 November 2018.

Non-Executive Director Options will vest on 15 November 2016, subject to the Director continuing to provide services as a Director of the Company or as otherwise in accordance with the NEDSIP.

#### 4. Share Rights (Unlisted)

473,200 Share Rights will be granted with a vesting date of 15 November 2016, subject to the holder continuing to provide services to the Company. The other terms of the Share Rights are consistent with the terms of the Employee Incentive Plan as approved by shareholders at the annual general meeting held on 22 November 2013.

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

• the date from which they do

• the extent to which they participate for the next dividend, (in the case of a trust,

distribution) or interest payment

No – Upon vesting of the Performance Rights, Share Rights and Options into ordinary shares, the allotted and issued shares will rank equally in all respects with the existing class of quoted ordinary fully paid shares.

•	the extent	to which the	y do	not rank
	equally, oth	ner than in rela	tion to	o the next
	dividend,	distribution	or	interest
	payment			

5 Issue price or consideration

Nil

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) Performance and Share Rights issued to attract, retain and incentivise employees and service providers.

Non-Executive Director Share Rights and Options issued as part of the Non-Executive Directors' annual remuneration package.

6a Is the entity an \*eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h *in relation to the* +*securities the subject of this Appendix* 

Yes

6b The date the security holder resolution under rule 7.1A was passed

3B, and comply with section 6i

11 November 2015

6c Number of \*securities issued without security holder approval under rule 7.1 473,200

6d Number of \*securities issued with security holder approval under rule 7.1A

6e Number of \*securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

n/a

6f Number of \*securities issued under an exception in rule 7.2

35,124,200 (issued under Exception 9(b) of rule 7.2)

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	n/a	
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	n/a	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Listing Rule 7.1 capacity: Listing Rule 7.1A capacity: Total (see Annexure 1)	59,035,030 40,022,345 99,057,375
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	On or before 31 January 2010	5.

<sup>+</sup> See chapter 19 for defined terms.

8 Number and \*class of all \*securities quoted on ASX (including the \*securities in section 2 if applicable)

Number +Class

400,486,095

\*This number does not include 4,000,000 shares issuable to Savanna Marble CC on the grant of a mining licence for the Etango Project (as approved by shareholders on 16 April 2009, 23 November 2010, 17 November 2011, 21 November 2012, 22 November 2013 and 4 November 2014).

9 Number and \*class of all \*securities not quoted on ASX (including the securities in section 2 if applicable)

, , ,	9, 23 November 2010,				
17 November 2011, 21 November 2012, 22					
	November 2013 and 4 November 2014).				
Number	+Class				
	<u>OPTIONS</u>				
	Non-Executive Directors				
4,504,000	A\$0.072 Options expiring 22 November 2016 (BMNAN)				
3,664,400	A\$0.089 Options expiring 15 November 2017 (BMNAN)				
7,846,000	A\$0.044 Options expiring 15 November 2018 (BMNAN)				
16,014,400	Total Options on issue				
	DEDECORMANCE/SHADE DIGHTS				
	PERFORMANCE/SHARE RIGHTS				
	Employees				
1,921,865	Performance Rights vesting 15 November 2016				
473,200	Share Rights vesting 15 November 2016				
5,095,630	Performance Rights vesting 22 November 2016				
12,662,829	Performance Rights vesting 15 November 2017				
21,482,300	Performance Rights vesting 15 November 2018				
	Non-Executive Directors				
862,100	Share Rights vesting 15 November 2016				
42,497,924	Total Performance and Share Rights on issue (BMNAAM)				
	OTHER				
1	Convertible Note with RCF Fund IV L.P. (convertible into 84,210,526 fully paid ordinary shares) (BMNAO)				
1	Convertible Note with RCF Fund VI L.P. (convertible into 42,105,263 fully paid ordinary shares) (BMNAO)				

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	No change
Part :	2 - Pro rata issue	
11	Is security holder approval required?	n/a
12	Is the issue renounceable or non-renounceable?	n/a
13	Ratio in which the *securities will be offered	n/a
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	n/a
15	<sup>+</sup> Record date to determine entitlements	n/a
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	n/a
17	Policy for deciding entitlements in relation to fractions	n/a
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.	n/a
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	n/a
20	Names of any underwriters	n/a
21	Amount of any underwriting fee or commission	n/a

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

22	Names of any brokers to the issue	n/a
	_	
23	Fee or commission payable to the broker to the issue	n/a
	_	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	n/a
	_	
25	If the issue is contingent on security holders' approval, the date of the meeting	n/a
	-	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	n/a
	_	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	n/a
28	Date rights trading will begin (if applicable)	n/a
29	Date rights trading will end (if applicable)	n/a
	L	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	n/a
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	n/a

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	n/a	
33	⁺Issu€	e date	n/a	
		uotation of securities complete this section if you are ap	<b>S</b> oplying for quotation of securities	
34	Type (tick o	of <sup>+</sup> securities one)		
(a)		<sup>+</sup> Securities described in Part	1	
(b)		All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entities that have ticked box 34(a)				
Additional securities forming a new class of securities				
Tick to docume		e you are providing the informat	ion or	
35			securities, the names of the 20 largest holders of the he number and percentage of additional *securities	
36			securities, a distribution schedule of the additional amber of holders in the categories	
37		A copy of any trust deed for	the additional <sup>+</sup> securities	

<sup>+</sup> See chapter 19 for defined terms.

## Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	n/a	
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	n/a	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	n/a	
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	n/a	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	n/a	Cluss

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>†</sup>quotation of the <sup>†</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

I LADUA

Sign here:	(Company secretary)	Date: 29 December 2015
Print name:	Robert Dalton 	

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B - Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	335,261,507	
Add the following:		
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	13,293,347	
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul>	51,668,597	
<ul> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> </ul>		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	0	
"A"	400,223,451	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	60,033,518	
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule	
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	998,488	
Under an exception in rule 7.2		
Under rule 7.1A		
With security holder approval under rule 7.1 or rule 7.4		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	998,488	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	60,033,518	
Note: number must be same as shown in Step 2		
Subtract "C"	998,488	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.15] – "C"	59,035,030	
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	400,223,451	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	40,022,345	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	0	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	0	

Appendix 3B Page 14 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	40,022,345	
Note: number must be same as shown in Step 2		
Subtract "E"	0	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	40,022,345	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.